DK2668160T3 - Trpm8-receptorantagonister - Google Patents

Trpm8-receptorantagonister Download PDF

Info

Publication number
DK2668160T3
DK2668160T3 DK12705078.9T DK12705078T DK2668160T3 DK 2668160 T3 DK2668160 T3 DK 2668160T3 DK 12705078 T DK12705078 T DK 12705078T DK 2668160 T3 DK2668160 T3 DK 2668160T3
Authority
DK
Denmark
Prior art keywords
chloronaphthalen
oxy
methyl
ylmethyl
amine
Prior art date
Application number
DK12705078.9T
Other languages
English (en)
Inventor
Alessio Moriconi
Gianluca Bianchini
Laura Brandolini
Andrea Aramini
Chiara Liberati
Silvia Bovolenta
Andrea Beccari
Simone Lorenzi
Original Assignee
Dompé Farmaceutici S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompé Farmaceutici S P A filed Critical Dompé Farmaceutici S P A
Application granted granted Critical
Publication of DK2668160T3 publication Critical patent/DK2668160T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)

Claims (12)

1. Forbindelser med formlen (I):
(I) og farmaceutisk acceptable salte deraf, hvor: R er valgt fra: - H, Br, CN, NO2, SO2NH2, S02NHR' og S02N(R')2, hvor R' er valgt fra lineær eller forgrenet C1-C4 alkyl; X er valgt fra: - F, Cl, C1-C3 alkyl, NH2 og OH Y er valgt fra: - -O-, CH2, NH og SO2 RI og R2, uafhængigt fra hinanden, er valgt fra - H, F og lineær eller forgrenet C1-C4 alkyl; R3 og R4, uafhængigt fra hinanden, er valgt fra - H og lineær eller forgrenet C1-C4 alkyl; Z er valgt fra: - NR6 og R6R7N+, hvor R6 og R7, uafhængigt fra hinanden, er valgt fra: • H og lineær eller forgrenet C1-C4 alkyl R5 er en gruppe valgt fra: - H og lineær eller forgrenet C1-C4 alkyl Het er en heteroaryl gruppe valgt fra pyrrolyl, N-methylpyrrolyl, thiophenyl, furyl og pyridinyl, ikke-substitueret eller substitueret med en eller flere substituenter valgt fra F, Cl, CH3, NH2 og OH.
2. Forbindelserne ifølge krav 1, hvor, uafhængigt fra hinanden: R er valgt fra H, Br og CN. X er valgt fra F, Cl og C1-C3 alkyl; Y er valgt fra -O- , CH2, NH og SO2, RI og R2, uafhængigt fra hinanden, er valgt fra H, F og Chb; R3 og R4, uafhængigt fra hinanden, er valgt fra H og Chb; Z er valgt fra NR6 og R6R7N+, hvor R6 og R7, uafhængigt fra hinanden, er valgt fra H og Chb; R5 er valgt fra H og Chb;
3. Forbindelserne ifølge krav 1 eller 2, hvor, uafhængigt fra hinanden, R er valgt fra H og CN; X er valgt fra F og Cl; Y er valgt fra CH2, O og SO2; Z er valgt fra NH og N + (CH3)2; R5 er H, Het er substitueret med mindst en substituent valgt fra F, Cl og CH3.
4. Forbindelserne ifølge et hvilket som helst af kravene 1 til 3, hvor Het er 5-substitueret pyrrol-2-yl, 5-substitueret N-methylpyrrol-2-yl, 5- substitueret thiophen-2-yl eller 5- substitueret fur-2-yl.
5. Forbindelserne ifølge et hvilket som helst af kravene 1 til 4 valgt fra gruppen bestående af: 2-[(l-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)ethanaminium chlorid (1) 2-[(l-chloronaphthalen-2-yl)oxy]-N-[(5-methylfuran-2-yl)methyl]ethanaminium chlorid (2) N-[(5-chlorofuran-2-yl)methyl]-2-[(l-chloronaphthalen-2-yl)oxy]ethanaminium (3) 2-[(l-chloronaphthalen-2-yl)oxy]-N-[(5-chlorothiophen-2-yl)methyl]ethanaminium (4) 2-[(l-chloronaphthalen-2-yl)oxy]-N-(thiophen-2-ylmethyl)ethana minium (5) 2-[(l-chloronaphthalen-2-yl)oxy]-N-(pyridin-2-ylmethyl)ethanaminium (6) 2-[(l-chloronaphthalen-2-yl)oxy]-N-[(l-methyl-lH-pyrrol-2-yl)methyl]ethanaminium (7) l-[(l-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)-2-methylpropan-2-amin (8) l-[(l-chloronaphthalen-2-yl)oxy]-2-methyl-N-[(5-methylfuran-2-yl)methyl]propan-2-amin (9) N-[(5-chlorofuran-2-yl)methyl]-l-[(l-chloronaphthalen-2-yl)oxy]-2-methylpropan-2-amin (10) l-[(l-chloronaphthalen-2-yl)oxy]-N-[(5-chlorc>thiophen-2-yl)methyl]-2-methylpropan-2-amin (11) l-[(l-chloronaphthalen-2-yl)oxy]-2-methyl-N-(thiophen-2-ylmethyl)propan-2-amin (12) 1- [(l-chloronaphthalen-2-yl)oxy]-2-methyl-N-(pyridin-2-ylmethyl)propan- 2- amin (13) 1- [(l-chloronaphthalen-2-yl)oxy]-2-methyl-N-[(l-methyl-lH-pyrrol-2-yl)methyl]propan-2-amin (14) 2- [(l-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)propan-l-amin (15) 2-[(l-chlorc)naphthalen-2-yl)oxy]-N-[(5-methylfuran-2-yl)methyl] propan- 1- amin (16) N-[(5-chlorofuran-2-yl)methyl]-2-[(l-chloronaphthalen-2-yl)oxy]propan-l-amin (17) 2- [(l-chloronaphthalen-2-yl)oxy]-N-[(5-chlorothiophen-2-yl)methyl]propan-l-amin (18) 2-[(l-chloronaphthalen-2-yl)oxy]-N-(thiophen-2-ylmethyl)propan-1-amin (19) l-[(l-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)propan-2-amin (20) 1- [(l-chloronaphthalen-2-yl)oxy]-N-[(5-methylfuran-2-yl)methyl]propan- 2- amin (21) N-[(5-chlorofuran-2-yl)methyl]-l-[(l-chloronaphthalen-2-yl)oxy]propan-2-amin (22) l-[(l-chloronaphthalen-2-yl)oxy]-N-[(5-chlorothiophen-2-yl)methyl]propan-2-amin (23). 1- [(l-chloronaphthalen-2-yl)oxy]-N-(thiophen-2-ylmethyl)propan-2-amin (24) 2- [(l-chloronaphthalen-2-yl)sulfonyl]-N-(furan-2-ylmethyl)ethanamin (25) 2-[(l-chloronaphthalen-2-yl)sulfonyl]-N-[(5-methylfuran-2-yl)methyl]ethanamin (26) N-[(5-chlorofuran-2-yl)methyl]-2-[(l-chloronaphthalen-2-yl)sulfonyl]ethanamin (27) 2-[(l-chloronaphthalen-2-yl)sulfonyl]-N-[(5-chlorothiophen-2-yl)methyl]ethanamin (28) 2-[(l-chloronaphthalen-2-yl)sulfonyl]-N-(thiophen-2-ylmethyl)ethanamin (29) 2-[(l-chloronaphthalen-2-yl)sulfonyl]-N-(pyridin-2-ylmethyl)ethanamin (30) 2- [(l-chloronaphthalen-2-yl)sulfonyl]-N-[(l-methyl-lH-pyrrol-2-yl)methyl] ethanamin (31) 3- (l-chloronaphthalen-2-yl)-N-(furan-2-ylmethyl)propan-l-amin (32) 3-( l-chloronaphthalen-2-yl)-N-[(5-methylfu ran-2-yl)methyl] propan- 1-amin (33) N-[(5-chlorofuran-2-yl)methyl]-3-(l-chloronaphthalen-2-yl)propan-1-amin (34) 3-(l-chloronaphthalen-2-yl)-N-[(5-chlorothiophen-2-yl)methyl]propan-l-amin (35) 3-(l-chloronaphthalen-2-yl)-N-(thiophen-2-ylmethyl)propan-l-amin (36) 3-(l-chloronaphthalen-2-yl)-N-(pyridin-2-ylmethyl)propan-l-amin (37) 2-[(l-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)-N-methylethanamin (38) 2-[(l-chloronaphthalen-2-yl)oxy]-N-(fiiran-2-ylmethyl)-N,N-dimethylethanaminiumiodid (39) N-{2-[(l-chloronaphthalen-2-yl)oxy]ethyl}-l-(5-methylfuran-2-yl)ethanamin (40) N-(l-chloronaphthalen-2-yl)-N'-(furan-2-ylmethyl)ethan-l,2-diamin (41) N-(l-chloronaphthalen-2-yl)-N'-[(5-methylfuran-2-yl)methyl]ethan-l,2-diamin (42) N-[(5-chlorofuran-2-yl)methyl]-N'-(l-chloronaphthalen-2-yl)ethan-l,2-diamin (43) N-(l-chloronaphthalen-2-yl)-N'-[(5-chlorothiophen-2-yl)methyl]ethan-l,2-diamin (44) N-(l-chloronaphthalen-2-yl)-N'-(thiophen-2-ylmethyl)ethan-l,2-diamin (45) N-(l-chloronaphthalen-2-yl)-N'-(pyridin-2-ylmethyl)ethan-l,2-diamin (46) N-(l-chloronaphthalen-2-yl)-N'-[(l-methyl-lH-pyrrol-2-yl)methyl]ethan-1,2-diamin (47) 2-[(l-fluoronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)ethanamin (48) 2-[(l-fluoronaphthalen-2-yl)oxy]-N-[(5-methylfuran-2-yl)methyl]ethanamin (49) N-[(5-chlorofuran-2-yl)methyl]-2-[(l-fluoronaphthalen-2-yl)oxy]ethanamin (50) N-[(5-chlorothiophen-2-yl)methyl]-2-[(l-fluoronaphthalen-2-yl)oxy]ethanamin (51) 2-[(l-fluoronaphthalen-2-yl)oxy]-N-(thiophen-2-ylmethyl)ethanamin (52) 2-[(l-fluoronaphthalen-2-yl)oxy]-N-(pyridin-2-ylmethyl)ethanamin (53) 2-[(l-fluoronaphthalen-2-yl)oxy]-N-[(l-methyl-lH-pyrrol-2-yl)methyl]ethanamin (54) 5-chloro-6-{2-[(pyridin-2-ylmethyl)amino]ethoxy}naphthalen-2-carbonitril (55) 5-chloro-6-{2-[(furan-2-ylmethyl)amino]ethoxy}naphthalen-2-carbonitril (56) 5-chloro-6-(2-{[(5-methylfuran-2-yl)methyl]amino}ethoxy)naphthalen-2-carbonitril (57) 5-chloro-6-(2-{[(5-chlorofuran-2-yl)methyl]amino}ethoxy)naphthalen-2-carbonitril (58) 5-chloro-6-(2-{[(5-chlorothiophen-2-yl)methyl]amino}ethoxy)naphthalen-2-carbonitril (59) 5-chloro-6-{2-[(thiophen-2-ylmethyl)amino]ethoxy}naphthalen-2-carbonitril (60). 2-[(l-ethylnaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)ethanamin (61) 2,2-difluoro-2-[(l-fluoronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)ethanamin (62) 2-[(6-bromo-l-fluoronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)ethanamin (63)
6. Forbindelserne ifølge et hvilket som helst af kravene 1 til 5, valgt fra gruppen bestående af: 2-[(l-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)ethanaminium chlorid (1) 2-[(l-chloronaphthalen-2-yl)oxy]-N-(thiophen-2-ylmethyl)ethana minium (5) 2-[(l-chloronaphthalen-2-yl)oxy]-N-(pyridin-2-ylmethyl)ethanaminium (6) l-[(l-chloronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)-2-methylprc>pan-2-amin (8) 1- [(l-chloronaphthalen-2-yl)oxy]-2-methyl-N-(pyridin-2-ylmethyl)prc>pan- 2- amin (13) 1- [(l-chloronaphthalen-2-yl)oxy]-2-methyl-N-[(l-methyl-lH-pyrrol-2-yl)methyl]propan-2-amin (14) 2- [(l-chloronaphthalen-2-yl)sulfonyl]-N-(furan-2-ylmethyl)ethanamin (25) 3- (l-chloronaphthalen-2-yl)-N-(furan-2-ylmethyl)propan-l-amin (32) 3-(l-chloronaphthalen-2-yl)-N-[(5-methylfuran-2-yl)methyl]propan-l-amin (33) N-[(5-chlorofuran-2-yl)methyl]-3-(l-chloronaphthalen-2-yl)propan-l-amin (34) 3-(l-chloronaphthalen-2-yl)-N-[(5-chlorothiophen-2-yl)methyl]propan-l-amin (35) 2-[(l-fluoronaphthalen-2-yl)oxy]-N-(furan-2-ylmethyl)ethanamin (48) 2-[(l-fluoronaphthalen-2-yl)oxy]-N-(thiophen-2-ylmethyl)ethanamin (52) 2-[(l-fluoronaphthalen-2-yl)oxy]-N-(pyridin-2-ylmethyl)ethanamin (53) 5-chloro-6-{2-[(pyridin-2-ylmethyl)amino]ethoxy}naphthalen-2-carbonitril (55) 5-chloro-6-{2-[(thiophen-2-ylmethyl)amino]ethoxy}naphthalen-2-carbonitril (60).
7. Forbindelserne ifølge et hvilket som helst af kravene 1 til 6, til anvendelse i forebyggelsen og/eller behandlingen af lidelser og/eller sygdomme forbundet med aktiviteten af TRPM8 (Transient Receptor Potential kationkanal underfamilie M medlem 8), hvor lidelsen og/eller sygdommene, er valgt fra gruppen bestående af: inflammatoriske lidelser, iskæmi, smerte, urologiske sygdomme, slagtilfælde, psykiatriske lidelser og neurodegeneration.
8. Forbindelserne til anvendelse ifølge krav 7, hvor lidelsen og/eller sygdommene, er valgt fra kronisk smerte, neuropatisk smerte inklusiv kold allodyni og diabetisk neuropatisk smerte, postoperativ smerte, osteoartritisk smerte, rheumatoid arthritisk smerte, cancersmerte, neuralgi, fibromyalgi, neuropatier, algesi, nerveskade, migræne, hovedpine, kløe, irritable tyktarm og luftvejssygdomme, blæresyndrom, interstitial cystitis, detrusor overaktivitet (overaktiv blære), urinær inkontinens, neurogenisk detrusor overaktivitet (detrusor hyperreflexia), idiopatisk detrusor overaktivitet (detrusor instabilitet), godartet prostatisk hyperplasi, nedre urinvejssygdomme og nedre urinvejssymptomer angst og depression.
9. Farmaceutisk sammensætning omfattende som den aktive ingrediens mindst en forbindelse ifølge et hvilket som helst af kravene 1 til 8 i kombination med egnede excipienser og/eller fortyndingsmidler.
10. Den farmaceutiske sammensætning ifølge krav 9, egnet til at blive administreret intravesikalt, intravenøst, dermalt, oralt, og inhalatorisk.
11. Den farmaceutiske sammensætning ifølge et af kravene 9 eller 10, i formen af kontrolleret frigivelses formulering.
12. Fremgangsmåde til fremstilling af forbindelserne ifølge et hvilket som helst af kravene 1 til 8, omfattende de følgende trin: - at omsætte det aminiske mellemprodukt IA :
CIA) hvor X, RI, R2, R3, R4 og Z har de samme betydninger som de med formel (I) og Y'= O, CH2, NH og S, with R5CO-Het, hvor Het og R5 har de samme betydninger som de med formel (I), og efterfølgende tilføjer til reaktionsblandingen et mildt reduktionsmiddel, fortrinsvis natriumborhydrid, for derved at opnå forbindelsen (IB)
(IB) som sammenfalder med den endelige forbindelse med formel (I) i tilfældet Y'= O, CH2, NH, og i tilfældet Y'=S fremgangsmåden endvidere omfatter det følgende trin: - at oxidere forbindelsen (IB) for at opnå forbindelsen med formel (I) med Y=SC>2.
DK12705078.9T 2011-01-28 2012-01-27 Trpm8-receptorantagonister DK2668160T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11425021A EP2481727A1 (en) 2011-01-28 2011-01-28 TRPM8 receptor antagonists
PCT/EP2012/051292 WO2012101244A1 (en) 2011-01-28 2012-01-27 Trpm8 receptor antagonists

Publications (1)

Publication Number Publication Date
DK2668160T3 true DK2668160T3 (da) 2015-11-23

Family

ID=44513692

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12705078.9T DK2668160T3 (da) 2011-01-28 2012-01-27 Trpm8-receptorantagonister

Country Status (21)

Country Link
US (1) US8906946B2 (da)
EP (2) EP2481727A1 (da)
JP (1) JP6043298B2 (da)
KR (1) KR101872553B1 (da)
CN (1) CN103443077B (da)
AU (1) AU2012210472B2 (da)
CY (1) CY1116896T1 (da)
DK (1) DK2668160T3 (da)
EA (1) EA022943B1 (da)
ES (1) ES2552533T3 (da)
HK (1) HK1192228A1 (da)
HR (1) HRP20151163T1 (da)
HU (1) HUE026587T2 (da)
ME (1) ME02290B (da)
PL (1) PL2668160T3 (da)
PT (1) PT2668160E (da)
RS (1) RS54337B1 (da)
SI (1) SI2668160T1 (da)
SM (1) SMT201500296B (da)
WO (1) WO2012101244A1 (da)
ZA (1) ZA201305576B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013011188B1 (pt) 2010-11-05 2022-01-04 Senomyx, Inc Método não-médico para modular canal potencial de receptor transiente de melastina 8 (trpm8), método não-médico para modular a sensação de resfriamento de uma composição, método não-médico para induzir uma sensação de resfriamento em um humano ou animal e composto
MX362192B (es) * 2013-05-08 2019-01-08 Kissei Pharmaceutical Derivado de glicinamida alfa-sustituida.
JP6531102B2 (ja) * 2013-09-03 2019-06-12 サムスン エレクトロニクス カンパニー リミテッド ダウンリンク伝送方法及びユーザ端末装置
EP3356356B1 (en) * 2015-10-01 2021-05-26 Firmenich Incorporated Compounds useful as modulators of trpm8
EP3184524A1 (en) * 2015-12-21 2017-06-28 Dompé farmaceutici S.p.A. 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as trpm8 antagonists
CN113398124A (zh) 2016-06-13 2021-09-17 田边三菱制药株式会社 用于治疗或预防血管舒缩症状的组合物
WO2023217989A1 (en) 2022-05-12 2023-11-16 Syngenta Crop Protection Ag Alkoxy heteroaryl- carboxamide or thioamide compounds
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080214654A1 (en) 2004-10-13 2008-09-04 Bayer Healthcare Ag Substituted Benzyloxy-Phenylmethylamide Derivatives
WO2007017094A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted benzyloxy-phenylmethylcarbamate derivatives
WO2007017093A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 2-benzyloxy-benzoic acid amide derivatives
WO2007017092A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 4-benzyloxy-benzoic acid amide derivatives
WO2007080109A1 (en) 2006-01-16 2007-07-19 Bayer Healthcare Ag Substituded benzyloxy-phenylmethylurea derivatives
EP2029614B1 (en) 2006-05-10 2013-01-23 Janssen Pharmaceutica, N.V. Cold menthol receptor-1 antagonists
MX2010000690A (es) 2007-07-18 2010-06-25 Janssen Pharmaceutica Nv Sulfonamidas como moduladores de trpm8.
CN102325750A (zh) * 2008-12-18 2012-01-18 詹森药业有限公司 作为trpm8调节剂的磺酰胺
WO2010103381A1 (en) 2009-03-13 2010-09-16 Glenmark Pharmaceuticals S.A. Spirocyclic piperidine derivatives as trpm 8 modulators
MX2011011428A (es) 2009-05-01 2011-11-29 Raqualia Pharma Inc Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
BR112013011188B1 (pt) * 2010-11-05 2022-01-04 Senomyx, Inc Método não-médico para modular canal potencial de receptor transiente de melastina 8 (trpm8), método não-médico para modular a sensação de resfriamento de uma composição, método não-médico para induzir uma sensação de resfriamento em um humano ou animal e composto
EP2793883B1 (en) * 2011-12-19 2018-04-18 Dompé farmaceutici s.p.a. Trpm8 antagonists

Also Published As

Publication number Publication date
AU2012210472A1 (en) 2013-08-15
EP2668160B1 (en) 2015-08-12
SMT201500296B (it) 2016-01-08
EA022943B1 (ru) 2016-03-31
US8906946B2 (en) 2014-12-09
ZA201305576B (en) 2014-10-29
WO2012101244A1 (en) 2012-08-02
CN103443077A (zh) 2013-12-11
ME02290B (me) 2016-02-20
JP6043298B2 (ja) 2016-12-14
HK1192228A1 (zh) 2014-08-15
EP2668160A1 (en) 2013-12-04
KR101872553B1 (ko) 2018-06-28
RS54337B1 (en) 2016-02-29
PL2668160T3 (pl) 2016-01-29
CY1116896T1 (el) 2017-04-05
HRP20151163T1 (hr) 2015-12-04
KR20140019336A (ko) 2014-02-14
AU2012210472B2 (en) 2016-06-23
EP2481727A1 (en) 2012-08-01
HUE026587T2 (hu) 2016-06-28
PT2668160E (pt) 2015-11-24
SI2668160T1 (sl) 2016-01-29
US20140031398A1 (en) 2014-01-30
EA201391094A1 (ru) 2014-01-30
ES2552533T3 (es) 2015-11-30
CN103443077B (zh) 2016-05-18
JP2014512336A (ja) 2014-05-22

Similar Documents

Publication Publication Date Title
DK2668160T3 (da) Trpm8-receptorantagonister
RU2275360C2 (ru) Ортозамещенные азотсодержащие бисарильные соединения для применения в качестве ингибиторов калиевого канала, а также содержащие их фармацевтические композиции
JP4667384B2 (ja) イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法
JP2007525482A (ja) イオンチャネルリガンドとしてのアミド化合物およびその使用
RU2673245C2 (ru) Производные 4-аминометилбензойной кислоты
EP3309146A1 (en) Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
JPWO2002094261A1 (ja) 含窒素化合物からなるｃｘｃｒ４拮抗作用を有する薬剤
JP6319436B2 (ja) ２−アシルアミノチアゾール誘導体またはその塩
US11046662B2 (en) 2-aryl-4-hydroxy-1,3-thiazole derivatives useful as TRPM8-inhibitors in treatment of neuralgia, pain, COPD and asthma
WO2013078237A1 (en) N-arylylmethylindazole modulators of pparg
US20150329533A1 (en) Compounds capable of inhibiting voltage gated calcium ion channel, and pharmaceutical compositions comprising the same
KR20160096174A (ko) 키나제 저해제로서의 치환된 다이알킬(옥사이도)-λ⁴-설판일리덴 니코틴아마이드 유도체
CN115160269A (zh) 芳甲酰胺类衍生物作为nmdar的正性变构调节剂
CA3172149A1 (en) Selective non-cyclic nucleotide activators for the camp sensor epac1